Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.41 |
| ▸ | TUBB | P07437 | 4/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960866 | 1.00 | ABCB1 (1.00) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| SCHEMBL1960865 | 1.00 | ABCB1 (1.00) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| Hydrochloric Acid SCHEMBL1960476 | 0.99 | ABCB1 (0.98) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| Hydrochloric Acid SCHEMBL1960471 | 0.99 | ABCB1 (0.98) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| SCHEMBL1959109 | 0.88 | ABCB1 (0.79) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| SCHEMBL1959112 | 0.88 | ABCB1 (0.79) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| SCHEMBL2812616 | 0.87 | ABCB1 (0.76) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| SCHEMBL2815844 | 0.87 | ABCB1 (0.76) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| SCHEMBL1958501 | 0.87 | ABCB1 (0.77) | ABCB1ABCG2PDE4BTUBB4ATUBB | |
| Hydrochloric Acid SCHEMBL1958058 | 0.87 | ABCB1 (0.77) | ABCB1ABCG2PDE4BTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115969970-A | Combination of an ABCG2 inhibitor and SACITUZUMAB GOVITECAN | 免疫医疗公司 | 2023-04-18 | — | — | CN | claimed |
| EP-4121564-A1 | BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY | Immunomedics, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | claimed |
| EP-3972605-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2022-03-30 | — | — | EP | claimed |
| CN-114096250-A | Novel therapy for erythropoietic protoporphyrinopathy (EPP) and X-linked protoporphyrinopathy (XLP) | 匹兹堡大学联邦高等教育系统 | 2022-02-25 | — | — | CN | claimed |
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-01-20 | — | — | US | disclosed |
| CN-114096250-B | Therapies for erythropoiesis protoporphyria (EPP) and X-linked protoporphyria (XLP) | 匹兹堡大学 联邦高等教育系统 | 2025-01-14 | — | — | CN | disclosed |
| CN-115969970-A | Combination of an ABCG2 inhibitor and SACITUZUMAB GOVITECAN | 免疫医疗公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4121564-A1 | BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY | Immunomedics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115398010-A | Biomarkers for Goxatuzumab therapy | 免疫医疗公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | disclosed |
| EP-3972605-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114096250-A | Novel therapy for erythropoietic protoporphyrinopathy (EPP) and X-linked protoporphyrinopathy (XLP) | 匹兹堡大学联邦高等教育系统 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | ABCC3, ABCC2, ABCB7 | ABCB1 9/4885ABCG2 19/4885PDE4B 4269/4885 |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | XPA, TPX2, XPOT | ABCB1 12/4885ABCG2 69/4885PDE4B 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.